Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Gilead Files HIV Med Lenacapavir in Japan
Gilead Sciences said on June 2 that it has filed a new drug application in Japan for its long-acting antiviral lenacapavir, a capsid inhibitor, for the treatment of HIV-1 infection. The submission is supported by the results of a PII/III…
To read the full story
Related Article
- Gilead’s Multi-Drug Resistant HIV Med Now Available in Japan
September 14, 2023
- Japan Approves Gilead’s HIV Med Sunlenca, Listing Set for Aug. 9
August 2, 2023
BUSINESS
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- Nipro Recalls Febuxostat after Finding Expired API Use at Another Plant
July 23, 2026
- Novo’s Koriyama Plant Achieves Net-Zero CO2 Emissions
July 23, 2026
- Sanofi Files Dupixent for AFRS in Japan
July 23, 2026
- Nippon Shinyaku Licenses NS-025 to US Biotech Aquelys
July 23, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…